Objective To investigate the diagnosis and treatment methods of traumatic renal infarction.Methods A retrospective analysis was performed on 6 cases of traumatic renal infarction treated between September 2008 and February 2013.There were 5 males and 1 female,at age of 5-65 years (average,36.2 years).Causes of injury included vehicle collisions in 4 cases and high falls in 2.Out of 6 cases,segmental renal infarction was identified in 2 and total infarction in 4.According to American Association for the surgery of trauma renal trauma grading system,2 cases were classified to grade Ⅳ and 4 to grade Ⅴ.Results Three cases were managed conservatively,which showed segmental infarction in 1 case and total infarction in 2.Three cases underwent surgical exploration,followed by partial nephrectomy in 1 case,left kidney removal plus partial pancreectomy in 1 and right kidney removal in 1.There were no major complications intraoperatively or postoperatively and no cases received blood transfusion.Period of follow-up was 3-34 months.In conservative management,there were no renal atrophies in segmental renal infarction cases and some degree of atrophies in total renal infarction cases,but none presented with arterial hypertension.Conclusions Enhanced CT is the preferred diagnostic tool for evaluation of traumatic renal infarction.Conservative therapy is the optimal option for most cases,but nephrectomy is reserved for cases of infection or renal hypertension.

Objective To study the expression of cadherin 17 ( CDH17 ) in metanephric adenoma ( MA ) , and to explore the value of CDH 17 in the diagnosis of metanephric adenoma.Methods Immunohistochemical EnVision method was used to detect the expression of CDH 17, WT1, CD57, P504S and EMA in 21 cases of MAs, 16 epithelial-predominant Wilms tumors ( e-WT), and 20 solid variant of papillary renal cell carcinomas ( s-PRCC).The expression of CDH17 was also examined in other common renal epithelial tumors , including 10 cases of clear cell renal cell carcinomas ( CCRCC ) , 10 chromophobe renal cell carcinomas ( CHRCC), and 10 oncocytomas.Results Twenty (95.2%) of 21 cases of MAs demonstrated membranous CDH 17 immunoreactivity in all components ( acinar , tubular , and papillary ) , whereas only 1 (1/16) e-WT was positive for CDH17 and all s-PRCCs were negative ( P<0.05).WT1 was negative in s-PRCC and was positive in all cases of e-WT ( 16/16 ) and MA ( 100%,21/21 ).All MAs (100%) were strongly positive for CD57;however, this marker was also positive in 13 (13/16) e-WTs and 9 (45.0%,9/20) s-PRCCs.P504S was strongly positive in all s-PRCCs (100%), but reactivity was seen in 3 (14.3%,3/21) MAs and all e-WTs were negative.The positive rates of EMA in MAs, e-WTs and s-PRCCs were 19.0%(4/21),14/16 and 17/20, respectively.The sensitivity and specificity of CDH17 in the diagnosis of MA were 95% and 97%.CDH17 was negative in all cases of CCRCC , CHRCC and oncocytoma.Conclusions CDH17 is a highly sensitive and specific marker for MA and should be considered in the immunohistochemistry panel for distinguishing MA from its mimics and other common renal epithelial tumors.